nach oben

International Journal of Colorectal Disease

Erschienen in:

07.07.2022 | Research

Risk of colon cancer-related death in people who had cancer in the past

verfasst von: Jing Shi, Yingmei Li, Wei Song, Mingxue Wang, Linyu Zhang, Haobin Lian, Zhi He, Nijun Wei, Zilong Zheng, Juan Wen

Erschienen in: International Journal of Colorectal Disease | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

The rate of second primary malignancies (SPM) is gradually increasing. Yet, the risk of death from primary cancer vs. SPM is still not well understood. In this study, we investigated the survival of patients with colorectal cancer (as SPM) who had cancer in the past (prior cancer) and the risk factors of SPM death in this population.

Materials and methods

Based on the Surveillance, Epidemiology, and End Results (SEER) database, we identified 1866 colon cancer patients with prior cancer in our main cohort and 43,959 colon cancer patients, including 37,440 patients with colon cancer as only malignancy and 6519 patients with colon cancer as subsequent colon cancer (SCC), in a second cohort and 3429 colon cancer patients, including 2371 patients with prior colon cancer (PCC) and 1058 patients with colon cancer as SPM, in a third cohort. After propensity score matching, 6519 pairs of subjects were identified in second cohort.

Results

Patients with prior prostate and breast cancer had a higher risk of developing colon cancer compared to those with gastrointestinal cancer. Also, colon cancer patients with different prior cancer had different survival rates. Furthermore, except for prior lung cancer (52.78 vs. 25.93%), most subjects died due to colon cancer complications. The ratio of colon cancer deaths to prior cancer deaths in patients with a low stage and high stage was 1.51 and 6.64, respectively. In addition, colon cancer-specific survival (CSS) and OS rates were significantly lower in subjects with colon cancer as the SPM than in those with PCC. Also, compared with PCC, SPM was associated with OS and CSS with HR 1.59 (95 CI 1.43–1.78) and HR 2.00 (95% CI 1.70–2.36). Furthermore, compared with only colon cancer, SCC was associated with OS and CSS with HR 1.23 (95 CI 1.17–1.29) and HR 1.13 (95% CI 1.06–1.21).

Conclusions

Prior cancer was found to have an adverse impact on OS in patients with colon cancer (secondary cancer), most of whom died due to colon cancer as secondary cancer itself rather than prior cancer. Early detection and treatment strategies should be investigated in this population.

Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH (2011) Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev 20(10):1996–2005. https://doi.org/10.1158/1055-9965.EPI-11-0729CrossRefPubMedPubMedCentral

de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, Forsythe L, Scoppa S, Hachey M, Rowland JH (2013) Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 22(4):561–570. https://doi.org/10.1158/1055-9965.EPI-12-1356CrossRefPubMedPubMedCentral

Murphy CC, Gerber DE, Pruitt SL (2018) Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol 4(6):832–836. https://doi.org/10.1001/jamaoncol.2017.3605CrossRefPubMedPubMedCentral

Siegel RL (2020) KD Miller, A Jemal (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590CrossRefPubMed

Gross CP, Guo Z, McAvay GJ, Allore HG, Young M, Tinetti ME (2006) Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc 54(12):1898–1904. https://doi.org/10.1111/j.1532-5415.2006.00973.xCrossRefPubMed

Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME (2006) The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145(9):646–653. https://doi.org/10.7326/0003-4819-145-9-200611070-00006CrossRefPubMed

Sarfati D, Hill S, Blakely T, Robson B, Purdie G, Dennett E, Cormack D, Dew K (2009) The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer 9:116. https://doi.org/10.1186/1471-2407-9-116CrossRefPubMedPubMedCentral

Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW (1998) Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 82(11):2123–2134CrossRef

Zheng C, Jiang F, Lin H, Li S (2019) Clinical characteristics and prognosis of different primary tumor location in colorectal cancer: a population-based cohort study. Clin Transl Oncol 21(11):1524–1531. https://doi.org/10.1007/s12094-019-02083-1CrossRefPubMed

10.

Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE (2015) Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst 107(4). https://doi.org/10.1093/jnci/djv002

11.

He X, Wu W, Ding Y, Li Y, Si J, Sun L (2018) Excessive risk of second primary cancers in young-onset colorectal cancer survivors. Cancer Med 7(4):1201–1210. https://doi.org/10.1002/cam4.1437CrossRefPubMedPubMedCentral

12.

Amer MH (2014) Multiple neoplasms, single primaries, and patient survival. Cancer Manag Res 6:119–134. https://doi.org/10.2147/CMAR.S57378CrossRefPubMedPubMedCentral

13.

Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, Trajanoski Z (2015) Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol 16:64. https://doi.org/10.1186/s13059-015-0620-6CrossRefPubMedPubMedCentral

14.

Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M (2016) Magnitude of pd-1, pd-l1 and t lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol 11(3):345–351. https://doi.org/10.1007/s11523-015-0396-3CrossRefPubMed

15.

Zhang Q, Liu S, Parajuli KR, Zhang W, Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR, Myers L, You Z (2017) Interleukin-17 promotes prostate cancer via mmp7-induced epithelial-to-mesenchymal transition. Oncogene 36(5):687–699. https://doi.org/10.1038/onc.2016.240CrossRefPubMed

16.

Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CL (2009) A human colonic commensal promotes colon tumorigenesis via activation of t helper type 17 t cell responses. Nat Med 15(9):1016–1022. https://doi.org/10.1038/nm.2015CrossRefPubMedPubMedCentral

17.

Zhang Q, Liu S, Zhang Q, Xiong Z, Wang AR, Myers L, Melamed J, Tang WW, You Z (2014) Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate 74(8):869–879. https://doi.org/10.1002/pros.22805CrossRefPubMedPubMedCentral

18.

Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 86(3):s836–s842. https://doi.org/10.1093/ajcn/86.3.836SCrossRefPubMed

19.

Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132(6):2208–2225. https://doi.org/10.1053/j.gastro.2007.03.050CrossRefPubMed

20.

Meyerhardt JA, Ma J, Courneya KS (2010) Energetics in colorectal and prostate cancer. J Clin Oncol 28(26):4066–4073. https://doi.org/10.1200/JCO.2009.26.8797CrossRefPubMedPubMedCentral

21.

Huo D, Hetzel JT, Roy H, Rubin DT (2009) Association of colorectal cancer and prostate cancer and impact of radiation therapy. Cancer Epidemiol Biomarkers Prev 18(7):1979–1985. https://doi.org/10.1158/1055-9965.EPI-09-0241CrossRefPubMed

22.

Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I (2018) Brca1 and brca2 gene mutations and colorectal cancer risk: systematic review and meta-analysis. J Natl Cancer Inst 110(11):1178–1189. https://doi.org/10.1093/jnci/djy148CrossRefPubMed

23.

Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med 7(2):60PubMedPubMedCentral

24.

Harpaz N, Gatt YE, Granit RZ, Fruchtman H, Hubert A, Grinshpun A (2020) Mucinous histology, brca1/2 mutations, and elevated tumor mutational burden in colorectal cancer. J Oncol 2020:6421205. https://doi.org/10.1155/2020/6421205CrossRefPubMedPubMedCentral

25.

Garcia-Patino E, Gomendio B, Provencio M, Silva JM, Garcia JM, Espana P, Bonilla F (1998) Germ-line brca1 mutations in women with sporadic breast cancer: clinical correlations. J Clin Oncol 16(1):115–120. https://doi.org/10.1200/JCO.1998.16.1.115CrossRefPubMed

26.

Wood K, Hensing T, Malik R, Salgia R (2016) Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review. JAMA Oncol 2(6):805–812. https://doi.org/10.1001/jamaoncol.2016.0405CrossRefPubMed

27.

Smyth EC, Tarazona N, Peckitt C, Armstrong E, Mansukhani S, Cunningham D, Chau I (2016) Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified? Clin Colorectal Cancer 15(2):e53–e59. https://doi.org/10.1016/j.clcc.2015.11.003CrossRefPubMed

28.

McGuire V, Whittemore AS, Norris R, Oakley-Girvan I (2000) Survival in epithelial ovarian cancer patients with prior breast cancer. Am J Epidemiol 152(6):528–532. https://doi.org/10.1093/aje/152.6.528CrossRefPubMed

29.

Al-Husseini MJ, Saad AM, Mohamed HH, Alkhayat MA, Sonbol MB, Abdel-Rahman O (2019) Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria. BMC Cancer 19(1):863. https://doi.org/10.1186/s12885-019-6074-6CrossRefPubMedPubMedCentral

30.

Chen Q, Zhao S, Song Y, Gao P, Sun J, Chen X, Sun Y, Wang Z (2018) Do patients with second primary colorectal cancer hold the similar prognosis and therapeutic benefits as those with initial primary colorectal cancer? Biomed Res Int 2018:6172670. https://doi.org/10.1155/2018/6172670CrossRefPubMedPubMedCentral

31.

Li M, Li JY, Zhao AL, Gu J (2007) Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology 73(1–2):52–57. https://doi.org/10.1159/000120628CrossRefPubMed

32.

Riihimäki M, Thomsen H, Sundquist K, Hemminki K (2012) Colorectal cancer patients: what do they die of? Frontline Gastroenterol 3(3):143–149. https://doi.org/10.1136/flgastro-2012-100141

33.

Li Z, Wang K, Shi Y, Zhang X, Wen J (2020) Incidence of second primary malignancy after breast cancer and related risk factors-is breast-conserving surgery safe? A nested case-control study. Int J Cancer 146(2):352–362. https://doi.org/10.1002/ijc.32259CrossRefPubMed

34.

Molina-Montes E, Requena M, Sanchez-Cantalejo E, Fernandez MF, Arroyo-Morales M, Espin J, Arrebola JP, Sanchez MJ (2015) Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol 136(1):158–171. https://doi.org/10.1016/j.ygyno.2014.10.029CrossRefPubMed

35.

He XK, Wu W, Ding YE, Li Y, Sun LM, Si J (2018) Different anatomical subsites of colon cancer and mortality: a population-based study. Gastroenterol Res Pract 2018:7153685. https://doi.org/10.1155/2018/7153685CrossRefPubMedPubMedCentral

36.

Huang CW, Tsai HL, Huang MY, Huang CM, Yeh YS, Ma CJ, Wang JY (2015) Different clinicopathologic features and favorable outcomes of patients with stage iii left-sided colon cancer. World J Surg Oncol 13:257. https://doi.org/10.1186/s12957-015-0640-4CrossRefPubMedPubMedCentral

Titel: Risk of colon cancer-related death in people who had cancer in the past
verfasst von: Jing Shi
Yingmei Li
Wei Song
Mingxue Wang
Linyu Zhang
Haobin Lian
Zhi He
Nijun Wei
Zilong Zheng
Juan Wen
Publikationsdatum: 07.07.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: International Journal of Colorectal Disease / Ausgabe 8/2022
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-022-04202-x

Neu im Fachgebiet Chirurgie

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Risk of colon cancer-related death in people who had cancer in the past